Oritavancin for acute bacterial skin and skin structure infections

被引:11
作者
Messina, Julia A. [1 ,2 ]
Fowler, Vance G., Jr. [2 ,3 ]
Corey, G. Ralph [2 ,3 ]
机构
[1] Duke Univ, Dept Med, Durham, NC 27710 USA
[2] Duke Univ, Duke Clin Res Inst, Durham, NC 27710 USA
[3] Duke Univ, Dept Med, Med, Durham, NC 27710 USA
关键词
acute bacterial skin and skin structure infection; lipoglycopeptide; oritavancin; Staphylococcus aureus; SOFT-TISSUE INFECTIONS; SINGLE-DOSE ORITAVANCIN; STAPHYLOCOCCUS-AUREUS; COMPLICATED SKIN; UNITED-STATES; IN-VITRO; EXPERIMENTAL ENDOCARDITIS; STANDARD THERAPY; ECONOMIC BURDEN; VANCOMYCIN;
D O I
10.1517/14656566.2015.1026256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Inpatient treatment of acute bacterial skin and skin structure infections (ABSSSIs) exerts a significant economic burden on the healthcare system. Oritavancin is a concentration-dependent, rapid bactericidal agent approved for the treatment of ABSSSIs. Its prolonged half-life with one-time intravenous (i.v.) dosing offers a potential solution to this burden. In addition, oritavancin represents an alternative therapy for Streptococci and multidrug-resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Animal models have also shown promising results with oritavancin for other disease states including those that require long courses of i.v. therapy. Areas covered: This review covers oritavancin's basic chemistry, spectrum of activity, pharmacodynamics/pharmacokinetics and efficacy in clinical trials, and provides expert opinion on future directions. To compose this review, a search of PubMed was performed, and articles written in the English language were selected based on full text availability. Expert opinion: If oritavancin is proven to be a cost-effective strategy for outpatient treatment and prevents complications of prolonged i.v. therapy, it will be sought as an alternative antibiotic therapy for ABSSSIs. In addition, further clinical data demonstrating efficacy in Gram-positive infections requiring prolonged therapy such as endocarditis and osteomyelitis could support oritavancin's success in the current market.
引用
收藏
页码:1091 / 1098
页数:8
相关论文
共 43 条
[1]   In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans [J].
Ambrose, Paul G. ;
Drusano, George L. ;
Craig, William A. .
CLINICAL INFECTIOUS DISEASES, 2012, 54 :S220-S228
[2]  
[Anonymous], 48 INT C ANT AG CHEM
[3]   Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing [J].
Arhin, Francis F. ;
Sarmiento, Ingrid ;
Belley, Adam ;
McKay, Geoffrey A. ;
Draghi, Deborah C. ;
Grover, Parveen ;
Sahm, Daniel F. ;
Parr, Thomas R., Jr. ;
Moeck, Gregory .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (05) :1597-1603
[4]   Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin [J].
Baquir, Beverlie ;
Lemaire, Sandrine ;
Van Bambeke, Francoise ;
Tulkens, Paul M. ;
Lin, Lin ;
Spellberg, Brad .
CLINICAL INFECTIOUS DISEASES, 2012, 54 :S229-S232
[5]   Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection [J].
Belley, Adam ;
Arhin, Francis F. ;
Sarmiento, Ingrid ;
Deng, Hong ;
Rose, Warren ;
Moeck, Greg .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) :205-211
[6]   Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia [J].
Bhavnani, SM ;
Passarell, JA ;
Owen, JS ;
Loutit, JS ;
Porter, SB ;
Ambrose, PG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :994-1000
[7]   Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects [J].
Bhavnani, SM ;
Owen, JS ;
Loutit, JS ;
Porter, SB ;
Ambrose, PG .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (02) :95-102
[8]   Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection [J].
Boucher, Helen W. ;
Wilcox, Mark ;
Talbot, George H. ;
Puttagunta, Sailaja ;
Das, Anita F. ;
Dunne, Michael W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) :2169-2179
[9]   Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections [J].
Chambers, Henry F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) :2238-2239
[10]   Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study [J].
Corey, G. Ralph ;
Good, Samantha ;
Jiang, Hai ;
Moeck, Greg ;
Wikler, Matthew ;
Green, Sinikka ;
Manos, Paul ;
Keech, Richard ;
Singh, Rajesh ;
Heller, Barry ;
Bubnova, Natalia ;
O'Riordan, William .
CLINICAL INFECTIOUS DISEASES, 2015, 60 (02) :254-262